This is the authors' abstract. We don't add key points for this paper.
The results of this study indicate that both AUC₂₄ and Cmax serve as relatively accurate predictors of tobramycin efficacy. Additionally, given the significant increase in incidence of AKI, multidaily dosing of IV tobramycin should be avoided in pediatric and adult patients with CF.
No takes yet. Share an insight, caveat, or question.
Landmesser et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: